## EXHIBIT 7 (PUBLIC)

**DOCKET A L A R M** Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

## **RAI Strategic Holdings, Inc.**

and

**R.J. Reynolds Vapor Company** 

v.

Altria Client Services LLC, Philip Morris USA, Inc., and Philip Morris Products S.A.

Civil Action No. 1:20-cv-00393-LO-TC

Amended and Supplemental Opening Expert Report

of Paul K. Meyer

**TM Financial Forensics, LLC** 

April 26, 2021

Jalu My Paul K. Meyer

**R M** Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

for a license to the technology claimed in the '545 Patent through December 31, 2020.<sup>730</sup>

514. In addition, the reasonable royalty rate addressed above does not account for the '545 Patent's importance to the Accused VUSE Products receiving PMTA authorization from the FDA. I understand from Stacy Ehrlich that, without the battery safety features as expressed in the '545 Patent, it would be unlikely for the FDA to grant the VUSE PMTAs.<sup>731</sup> Furthermore,

<sup>732</sup> In my opinion, when considering the significant importance of the technology claimed in the '545 Patent to the PMTA authorization process (in addition to the considerations that formed my basis for the **or** royalty rate), a **or** reasonable royalty rate would result from the hypothetical negotiation between the parties. From a royalty valuation and financial and economic perspective, the increased royalty is reasonable as it allows Reynolds to avoid identified PMTA authorization risks and considers: (1) the investments made by Reynolds in the Accused VUSE Products; (2) the significant commercial success achieved by the Accused VUSE Products including sales and market share;<sup>733</sup> and (3) RJRV's investments in the accused product PMTAs.

515. Applying a royalty rate to RJRV's net sales of Accused VUSE Products for the '545 Patent of the '545 Patent of the '545 (based on the sales data available to date), results in royalty damages of the technology claimed in the '545 Patent through December 31, 2020.<sup>734</sup>

<sup>&</sup>lt;sup>730</sup> Attachment 5A.U.

<sup>&</sup>lt;sup>731</sup> Based on discussions with Mr. McAlexander; Based on discussions with Ms. Ehrlich.

<sup>&</sup>lt;sup>732</sup> [ITC] Deposition of James N. Figlar (Executive Vice President of Scientific and Regulatory Affairs and R&D at Reynolds), September 25, 2020: pp. 50; Expert Report of Nisha M. Mody, Ph.D. dated October 5, 2020, In the Matter of Certain Tobacco Heating Articles and Components ThereOf, United States International Trade Commission, INV. No. 337-TA-1199, pp. 98-99. *See also*, Deposition of Eric Hunt (Senior Manager, RJRV Vapor Products Development), April 14, 2021: p. 306.

<sup>&</sup>lt;sup>733</sup> See Attachments 6, 12.1.U and Attachment 17.U series.

<sup>&</sup>lt;sup>734</sup> Attachment 5A.U.